- Investing Ideas
- Hong Kong Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
Hong Kong Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
Results
6
Companies with promising cash flow potential yet trading below their fair value, as determined by SWS DCF valuation, signaling opportunity for value-oriented investors.
6 companies
CanSino Biologics
Market Cap: HK$9.8b
Develops, manufactures, and commercializes vaccines in the People’s Republic of China.
6185
HK$23.10
7D
-1.3%
1Y
-47.9%
Akeso
Market Cap: HK$86.5b
A biopharmaceutical company, engages in the research, development, manufacture, and commercialization of antibody drugs worldwide.
9926
HK$91.95
7D
-6.7%
1Y
-39.5%
Biocytogen Pharmaceuticals (Beijing)
Market Cap: HK$47.1b
A biotechnology company, engages in the research and development of novel antibody-based drugs and pre-clinical research services in the People’s Republic of China, the United States, and internationally.
2315
HK$52.45
7D
-3.0%
1Y
99.1%
InSilico Medicine Cayman TopCo
Market Cap: HK$26.2b
Engages in applying artificial intelligence (AI) solutions to drug discovery and development by leveraging its proprietary platforms.
3696
HK$42.18
7D
-11.7%
1Y
n/a
Frontage Holdings
Market Cap: HK$2.4b
Provides drug discovery, drug development, pharmaceutical product development, and laboratory testing services to pharmaceutical, biotechnology, and agrochemical companies.
1521
HK$1.21
7D
5.2%
1Y
-17.1%
WuXi XDC Cayman
Market Cap: HK$65.6b
An investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally.
2268
HK$51.25
7D
-5.7%
1Y
-10.9%